Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$22.47 -3.9%	$21.67	$12.21 ▼ $41.31	$686.92M	-0.26	638,835 shs	545,336 shs
CYBN Cybin	$8.15 -5.0%	$7.50	$4.81 ▼ $13.88	$187.40M	0.68	269,398 shs	182,543 shs
NUVB Nuvation Bio	$1.94 -1.4%	$2.15	$1.54 ▼ $3.97	$670.32M	1.37	2.92 million shs	14.17 million shs
URGN Urogen Pharma	$13.49 +2.9%	$9.34	$3.42 ▼ $18.15	$604.47M	0.4	1.07 million shs	2.27 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-3.89%	-3.02%	+7.51%	+18.58%	-7.23%
CYBN Cybin	-5.01%	+4.76%	+0.62%	+21.28%	+2,108.67%
NUVB Nuvation Bio	-0.66%	-0.66%	-11.32%	+7.00%	-35.05%
URGN Urogen Pharma	+2.90%	-7.92%	+233.09%	+20.45%	-21.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	2.4595 of 5 stars	3.4	1.0	0.0	3.8	1.7	0.6
CYBN Cybin	2.9295 of 5 stars	3.6	0.0	0.0	3.4	0.8	1.3
NUVB Nuvation Bio	3.5485 of 5 stars	4.6	0.0	0.0	3.1	5.0	0.0
URGN Urogen Pharma	4.5841 of 5 stars	4.5	2.0	4.5	2.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$42.38	88.58% Upside
CYBN Cybin	3.25	Buy	$86.00	955.21% Upside
NUVB Nuvation Bio	3.20	Buy	$7.17	269.04% Upside
URGN Urogen Pharma	3.00	Buy	$32.86	143.57% Upside

Current Analyst Ratings Breakdown

Latest CYBN, ANAB, URGN, and NUVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/16/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
6/13/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$16.00
6/13/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Buy	$31.00
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$23.00 ➝ $47.00
6/13/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $30.00
6/12/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$91.28M	7.23	N/A	N/A	$2.33 per share	9.64
CYBN Cybin	N/A	N/A	N/A	N/A	$10.83 per share	N/A
NUVB Nuvation Bio	$7.87M	83.96	N/A	N/A	$1.37 per share	1.42
URGN Urogen Pharma	$90.40M	6.88	N/A	N/A	($0.21) per share	-64.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.85	N/A	N/A	N/A	-125.70%	-282.47%	-30.79%	8/4/2025 (Estimated)
CYBN Cybin	-$57.88M	-$4.38	N/A	N/A	N/A	N/A	-37.58%	-36.59%	N/A
NUVB Nuvation Bio	-$567.94M	-$2.35	N/A	N/A	N/A	-5,534.21%	-44.14%	-32.97%	8/4/2025 (Estimated)
URGN Urogen Pharma	-$126.87M	-$3.18	N/A	N/A	N/A	-150.68%	-97,487.15%	-49.57%	8/12/2025 (Estimated)

Latest CYBN, ANAB, URGN, and NUVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	URGN Urogen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	-$0.16	N/A	-$0.16	$0.42 million	$3.08 million
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
CYBN Cybin	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.25	8.25
CYBN Cybin	N/A	24.24	24.24
NUVB Nuvation Bio	N/A	9.01	9.01
URGN Urogen Pharma	4.77	5.65	5.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
CYBN Cybin	17.94%
NUVB Nuvation Bio	61.67%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
CYBN Cybin	15.00%
NUVB Nuvation Bio	29.93%
URGN Urogen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.38 million	19.54 million	Optionable
CYBN Cybin	50	22.99 million	17.96 million	Not Optionable
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable
URGN Urogen Pharma	200	46.11 million	43.76 million	Optionable

CYBN, ANAB, URGN, and NUVB Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 27 at 10:00 AM | prnewswire.com

Urogen Pharma (NASDAQ:URGN) Trading Down 5.3% - Time to Sell?

June 24, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Analysts

June 24, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Buy" by Brokerages

June 24, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 23, 2025 | globenewswire.com

Lowey Dannenberg Notifies UroGen Pharma Ltd. (â€œUroGenâ€ or the â€œCompanyâ€) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

June 23, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 22, 2025 | prnewswire.com

Stocks With Rising Relative Price Strength: UroGen Pharma

June 20, 2025 | msn.com

HC Wainwright Has Negative View of Urogen Pharma Q2 Earnings

June 20, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Trading 10.3% Higher - Here's What Happened

June 18, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 18, 2025 | globenewswire.com

HC Wainwright Decreases Earnings Estimates for Urogen Pharma

June 18, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Raised to "Buy" at HC Wainwright

June 18, 2025 | americanbankingnews.com

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy

June 17, 2025 | msn.com

UroGen Pharma (NASDAQ:URGN) Trading Down 7.7% - Time to Sell?

June 17, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 17, 2025 | prnewswire.com

UroGen Pharma Ltd. (NASDAQ:URGN) Short Interest Down 29.9% in May

June 17, 2025 | marketbeat.com

URGN SHAREHOLDER ALERT: BFA Law Reminds UroGen Pharma Ltd. Investors of Upcoming July 28 Class Action Deadline - Contact The Firm if You Suffered Losses

June 16, 2025 | accessnewswire.comA

Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGN

June 16, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in UroGen Pharma Ltd. of Class Action Lawsuit And Upcoming Deadlines - URGN

June 16, 2025 | accessnewswire.comA

UroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst Upgrade

June 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYBN, ANAB, URGN, and NUVB Company Descriptions

AnaptysBio NASDAQ:ANAB

$22.47 -0.91 (-3.89%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$22.06 -0.40 (-1.80%)

As of 06/27/2025 06:03 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Cybin NYSE:CYBN

$8.15 -0.43 (-5.01%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.19 +0.04 (+0.49%)

As of 06/27/2025 07:35 PM Eastern

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Nuvation Bio NYSE:NUVB

$1.94 -0.03 (-1.42%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$1.94 +0.00 (+0.15%)

As of 06/27/2025 07:59 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Urogen Pharma NASDAQ:URGN

$13.49 +0.38 (+2.90%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.62 +0.13 (+0.93%)

As of 06/27/2025 07:50 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time